Page last updated: 2024-12-11

schisantherin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

schisantherin B: lignan isolated from fruit of Schisandra sphenanthera; RN given refers to schisanterin B and gomisin B [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438572
CHEMBL ID490308
CHEBI ID81352
MeSH IDM0218847

Synonyms (29)

Synonym
AC-20312
gomisin b
58546-55-7
schisantherin b
(hydroxy-tetramethoxy-dimethyl-[?]yl) (z)-2-methylbut-2-enoate
schisandrer b
2-butenoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethylbenzo(3,4)cycloocta(1,2-f)(1,3)benzodioxol-5-yl ester, (5s-(5.alpha.(z),6.beta.,7.beta.))-
schisantherin c
C17814
CHEMBL490308
chebi:81352 ,
AKOS015965248
97ztc185xv ,
2-butenoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethylbenzo(3,4)cycloocta(1,2-f)(1,3)benzodioxol-5-yl ester, (5s-(5alpha(z),6beta,7beta))-
wuweizi ester b
unii-97ztc185xv
AC-34853
2-butenoic acid, 2-methyl-, (5s,6s,7s,13as)-5,6,7,8-tetrahydro-6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethylbenzo(3,4)cycloocta(1,2-f)(1,3)benzodioxol-5-yl ester, (2z)-
Q27155290
(5s,6s,7s)-6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxol-5-yl (z)-2-methylbut-2-enoate
2-butenoic acid, 2-methyl-, (5s,6s,7s,13as)-5,6,7,8-tetrahydro-6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-f][1,3]benzodioxol-5-yl ester, (2z)-
CCG-269808
wuweizi ester-b
gomisin-b
schizantherin-b
S9443
G0540
2-butenoicacid,2-methyl-,(5s,6s,7s,13as)-5,6,7,13a-tetrahydro-6-hydroxy-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-f][1,3]benzodioxol-5-ylester,(2z)-
[(8s,9s,10s)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-yl] (z)-2-methylbut-2-enoate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" During the application of TCM, the researches about bioavailability enhancement of the bioactive constituents in formula are flourishing."( Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
Chen, JM; Fang, JS; Huang, MJ; Li, WR; Liang, Y; Lin, MJ; Liu, JM; Ma, CR; Wang, Q; Wu, FC; Yu, WQ; Zuo, X, 2022
)
0.72
"The aim of this study is to explore the material basis and molecular mechanism from BSYZ in the bioavailability enhancement of OST."( Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
Chen, JM; Fang, JS; Huang, MJ; Li, WR; Liang, Y; Lin, MJ; Liu, JM; Ma, CR; Wang, Q; Wu, FC; Yu, WQ; Zuo, X, 2022
)
0.72
"Schisantherin B, a profoundly effective CYP3A4 inhibitor screened from BSYZ antagonized the metabolism of CYP3A4 on OST via activity inhibition, therefore significantly enhanced the bioavailability of OST in rat plasma."( Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
Chen, JM; Fang, JS; Huang, MJ; Li, WR; Liang, Y; Lin, MJ; Liu, JM; Ma, CR; Wang, Q; Wu, FC; Yu, WQ; Zuo, X, 2022
)
2.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tanninAny of a group of astringent polyphenolic vegetable principles or compounds, chiefly complex glucosides of catechol and pyrogallol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID379885Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B2006Journal of natural products, Dec, Volume: 69, Issue:12
Rubrisandrins A and B, lignans and related anti-HIV compounds from Schisandra rubriflora.
AID569567Therapeutic index, ratio of CC50 for human C1866 cells to EC50 for HIV1-3B2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Compounds from Kadsura angustifolia with anti-HIV activity.
AID379883Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA2006Journal of natural products, Dec, Volume: 69, Issue:12
Rubrisandrins A and B, lignans and related anti-HIV compounds from Schisandra rubriflora.
AID379884Cytotoxicity against human H9 cells after 4 days2006Journal of natural products, Dec, Volume: 69, Issue:12
Rubrisandrins A and B, lignans and related anti-HIV compounds from Schisandra rubriflora.
AID569565Cytotoxicity against human C1866 cells2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Compounds from Kadsura angustifolia with anti-HIV activity.
AID569566Antiviral activity against HIV1-3B infected in human C1866 cells assessed as inhibition of virus-induced cytopathic effect2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Compounds from Kadsura angustifolia with anti-HIV activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (23.08)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's4 (30.77)24.3611
2020's4 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]